Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

Company Overview

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Key Stats

• Today's Range: $0.29 to $0.31
• 50-Day Range: $0.25 to $0.34
• 52-Week Range: $0.24 to $0.88
• Volume: 2.06 million shs
• Average Volume: 1.94 million shs
• Market Capitalization: $376.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Northwest Biotherapeutics Stock Analysis - MarketRank™

Northwest Biotherapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Northwest Biotherapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Northwest Biotherapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Northwest Biotherapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.64% of the outstanding shares of Northwest Biotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Northwest Biotherapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Northwest Biotherapeutics has recently decreased by 2.03%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Northwest Biotherapeutics does not currently pay a dividend.

Dividend Growth

Northwest Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.64% of the outstanding shares of Northwest Biotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Northwest Biotherapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Northwest Biotherapeutics has recently decreased by 2.03%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.69

News Sentiment

Northwest Biotherapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Northwest Biotherapeutics this week, compared to 0 articles on an average week.

Search Interest

8 people have searched for NWBO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of Northwest Biotherapeutics is held by insiders.

Percentage Held by Institutions

Only 0.04% of the stock of Northwest Biotherapeutics is held by institutions.

NWBO Stock Analysis - Frequently Asked Questions

How have NWBO shares performed this year?

Northwest Biotherapeutics' stock was trading at $0.7010 on January 1st, 2024. Since then, NWBO stock has decreased by 58.6% and is now trading at $0.2901.
View the best growth stocks for 2024 here.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its earnings results on Monday, August, 10th. The biotechnology company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.20 million.

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/10/2015
• Today: 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NWBO
• Previous Symbol: NASDAQ:NWBO
• CUSIP: N/A
• CIK: 1072379
• Web: www.nwbio.com
• Phone: (240) 497-9024
• Fax: 240-627-4121
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-62,600,000.00
• Net Margins: -4,666.29%
• Pretax Margin: -4,479.03%
• Return on Equity: N/A
• Return on Assets: -263.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 194.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -4.84

Miscellaneous

• Outstanding Shares: 1,297,090,000
• Free Float: 1,184,241,000
• Market Cap: $376.29 million
• Optionable: Not Optionable
• Beta: -0.55